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I schemic stroke is a major cause of morbidity and mortality,  and there are limited therapeutic options.  
Because of the short therapeutic time window in isch-
emic stroke,  many patients suffer from severe disabili-
ties,  even if they receive timely interventional or 
thrombolytic therapies [1].  In recent years,  stem cell 
transplantation has emerged as a new approach for the 
treatment of ischemic stroke [2-6].  There are several 
cell sources for stem cell therapy for ischemic stroke.  
Among them,  mesenchymal stem cells (MSCs) have the 
advantage of being rapidly isolated from bone marrow 
and do not require a long culture time,  making them 
well suited for autologous administration even in the 
acute phase of stroke [7].  MSC transplantation 
approaches include intracerebral,  intravenous,  and 
intra-arterial transplantation [4 , 5 , 8-26].  The mecha-
nisms of MSC transplantation for ischemic stroke are 
mainly considered based on their neuroprotective 
effects [2-4 , 8 , 10 , 14 , 16 , 17 , 21 , 22 , 25 , 27-30].  MSCs 
can differentiate into various types of cells,  such as 
endothelial cells and neuronal cells [3 , 28].  Moreover,  
the benefits of MSC transplantation have been ascribed 
to the secretion of neurotrophic factors or chemotactic 
cytokines from transplanted MSCs [2 , 3 , 24 , 28 , 30].  In 
addition to the secretory function,  migration of MSCs 
into the infarct area and the reduction of the infarct 
volumes after transplantation can mediate the neuro-
protective effects [2-4 , 14 , 28].  Therefore,  both animal 
and clinical studies have confirmed the therapeutic 
effect of MSC transplantation in ischemic stroke [1].  In 
the past few years,  some preliminary phase I/II trials 
have identified the safety and feasibility of autologous 
MSC transplantation in ischemic stroke patients [5 , 31-
34 , 48 , 51 , 55 , 56].  In this review,  recent findings on 
MSC therapy are described,  as well as the current status 
of MSC therapy for ischemic stroke.
MSC Transplantation Approaches
Intracerebral transplantation. The advantage of 
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intracerebral transplantation is the targeted deposition 
of stem cells into the lesioned brain,  compared to intra-
vascular transplantation (intravenous or intra-arterial 
transplantation),  which results in the majority of the 
cells being lodged in peripheral organs [12 , 26].  
However,  intracerebral transplantation is more invasive 
than intravascular transplantation,  with the added pos-
sibility of adding new injury to brain tissue [35].
Intravenous transplantation. Intravenous trans-
plantation is the simplest and safest method,  compared 
to intracerebral or intra-arterial transplantation [11].  
Therefore,  intravenous MSC transplantation was most 
commonly used for ischemic stroke animals and patients 
in the past.  Unfortunately,  the transplanted cells must 
pass through the systemic and pulmonary circulation 
systems.  Cell replacement is therefore difficult to achieve 
by intravenous MSC transplantation,  and there are tro-
phic effects of MSCs to consider as well [2 , 11].
Intra-arterial transplantation. Intra-arterial 
transplantation falls somewhere between intravenous 
and intracerebral transplantation due to it being rela-
tively less invasive and the number of cells reaching the 
lesion site.  A higher number of human MSCs migrated 
into the infarct lesion with intra-arterial transplantation 
than with intravenous transplantation,  resulting in bet-
ter functional recovery in animal stroke models [4 , 14].  
On the other hand,  intra-arterial transplantation carries 
the risks of cerebral embolism and the reduction of 
cerebral blood flow associated with microstrokes [36].
Therapeutic Effects of MSC Therapy on 
Ischemic Stroke Model of Animals
Mechanisms of MSC therapy. MSCs contribute to 
the treatment of cerebral ischemia through multiple 
mechanisms,  including cell migration,  angiogenesis,  
prevention of apoptosis,  secretion of neurotrophic fac-
tors,  neural circuit reconstruction,  and immunomod-
ulation [1].  Mainly,  MSCs exert neuroprotective effects 
through cell migration into the infarct area with the 
subsequent secretion of neurotrophic factors.
MSC migration into the infarct area. Previous 
reports have revealed that transplanted MSCs mainly 
migrate into the ischemic penumbra and the subven-
tricular zone [1 , 37 , 38].  Microglia and astrocytes in the 
infarct area secrete stromal cell-derived factor 1 (SDF-
1).  MSCs express chemokine receptor 4 (CXCR-4),  the 
physiological receptor for SDF-1.  The interaction of 
SDF-1 and CXCR-4 causes MSC migration into the 
infarct area [1 , 39 , 40].  A lack of CXCR-4 or SDF-1α 
will significantly reduce the targeted migration of MSCs 
[41].  These mechanisms are one of the causes of MSC 
migration.  However,  the manner in which MSCs pass 
the blood-brain barrier remains poorly understood.
Neurotrophic factors secreted by MSC. Several 
neurotrophic factors have been shown to contribute to 
the therapeutic outcomes of stem cell therapy in exper-
imental stroke.  In vitro studies show that MSCs secrete 
at least 11 kinds of neurotrophic factors after co-culture 
with cortical neurons under hypoxic conditions [42].  
MSCs have neuroprotective effects in the early stage of 
transplantation in rats with cerebral ischemia [43].  
MSCs also induce parenchymal cells in the host tissue to 
secrete nerve growth factor,  brain-derived neuro-
trophic factor (BDNF),  glial cell line-derived neuro-
trophic factor (GDNF),  epidermal growth factor,  basic 
fibroblast growth factor,  insulin-like growth factor 1,  
hepatocyte growth factor,  and stem cell factor [4 , 28 ,  
44 , 45 , 46 , 47].  These neurotrophic factors promote 
functional recovery after stroke through the reduction 
of apoptosis and inflammation,  proliferation of endog-
enous stem and progenitor cells within the peri-in-
farcted tissue,  angiogenesis,  and neurogenesis [1 , 28-
30 , 35].
Clinical application of MSC transplantation for 
ischemic stroke patients. In Table 1,  recent clinical 
trials involving MSC transplantation in ischemic stroke 
patients are listed.  Initially,  there were a few reports on 
intracerebral transplantation.  In one study,  five chronic 
stage patients received stereotactic transplantation of 
autologous bone marrow stem cells [48].  There were no 
adverse events after surgery,  and some patients showed 
improved neurological function.  However,  because of 
the small number of patients,  these results demon-
strated only the safety of intracerebral transplantation.  
In contrast,  there are several studies on intravenous 
transplantation as a less invasive method.  In 2005,  
autologous intravenous MSC transplantation was started 
for ischemic stroke patients.  In this phase I random-
ized study,  five patients received intravenous adminis-
tration of 1 × 108 MSCs with subsequent functional 
recovery [49].  There were no adverse events,  such as 
venous thromboembolism,  abnormal cell proliferation,  
systemic cancer,  systemic infection,  or neurological 
decline after intravenous MSCs transplantation [50 ,  
51 , 52].  In 2014,  the first phase II randomized clinical 
trial of intravenous allogeneic MSC transplantation in 
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ischemic stroke patients was reported [53].  In this 
study,  the therapeutic effect of intravenous allogeneic 
MSC transplantation was shown in sub-acute stage 
patients.  These results indicate the safety,  feasibility,  
and therapeutic effects of intravenous MSC transplan-
tation in ischemic stroke patients.  For over a decade,  
MSC transplantation has been shown to have therapeu-
tic effects on stroke patients.  Moreover,  a phase III 
randomized clinical trial of intravenous allogeneic MSC 
transplantation on chronic stage patients is ongoing 
[54].  On the other hand,  several clinical studies have 
suggested the beneficial neuroprotective effects of 
intra-arterial MSCs transplantation for ischemic stroke 
patients in recent years.  The initial studies have shown 
that autologous intra-arterial MSC transplantation in 
ischemic stroke patients in the sub-acute phase was safe 
and feasible and free of adverse events [5 , 55 , 56].  In 
one study,  patients with moderate to severe ischemic 
stroke were treated within 3 to 7 days after onset.  No 
observable complications were found,  and 40% of the 
patients showed a good clinical outcome at the chronic 
phase [53].  However,  the optimal time window is still 
unclear.  It is very difficult to argue the timing of cell 
transplantation for stroke patients because the condi-
tion of patients with ischemic stroke varies remarkably.  
A clinical trial of intra-arterial MSC transplantation in 
acute ischemic stroke is ongoing [57].  Furthermore,  
the current study revealed a strong correlation between 
intra-arterial transplanted cell dose and patient out-
come [7].  A cutoff point of 310 × 106 injected cells pre-
dicted a good outcome with 80% sensitivity and 88.2% 
specificity,  although additional basic and clinical stud-
ies are needed.  A very recent phase I/II study of intra-
cerebral cell transplantation for stroke patients reported 
positive data using genetically modified MSCs [58].  
This study showed the safety and clinical improvement 
at 12 months after transplantation.  The neuromodula-
tion by the cell transplantation might be strongly related 
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Table 1　 Recent clinical trials with MSC transplantation in ischemic stroke patients
Author Number of patients Cell type Route Cell dose Time window Result
Bang 2005 [49] 5 MSC IV 1×108 N/A Safe and eﬀective
Suárez-Monteagudo
2009 [48] 5 BMSC IC 1.4-5.5×10
7 1-10 years Safe
Bhasin 2011 [51] 6 BMSC IV 5-6×107 6 months- 1 year Safe and feasible
Savitz 2011 [34] 10 BMNC IV 10 million cells/kg 24-72 hours Safe and feasible
Battistela 2011 [55] 6 BMNC IA 1.5×108 Within 90 days Safe and feasible
Moniche 2012 [5] 10 BMNC IA 1.59×108 5-9 days Safe and feasible
Friedrich 2012 [56] 20 BMNC IA 2.3×108 3-7 days Safe and feasible
Diez-Tejedor 2014 [53] 10 MSC IV N/A 2 weeks Safe and eﬀective
Moniche 2015 [57] 76 BMNC IA
2×106/kg
or
5×106/kg
N/A Ongoing
Steinburg 2016 [58] 18 modiﬁedMSC IC
2.5×106 or
5.0×10 or
10×106
2 years Eﬀective
Moniche 2016 [7] 22 BMNC IA 1.53×108 5-9 days Eﬀective
Honmou. 2016 [54] N/A MSC IV N/A Within 40 days Ongoing
BMNC,  bone marrow mononuclear cell; BMSC,  bone marrow stem cell; MSC,  mesenchymal stem cell; IA,  intra-arterial; IC,  intracere-
bral; IV,  intravenous.
to the therapeutic effects.  We are now proceeding to an 
international multi-center clinical trial for traumatic 
brain injuries using these promising genetically modi-
fied MSCs.
Conclusions
The main approaches of MSC transplantation for 
ischemic stroke,  the mechanisms of MSC therapy,  and 
the current clinical studies have been shown in this 
review article.  To date,  many animal studies and sev-
eral clinical studies have investigated the optimal tim-
ing,  approach of transplantation,  and cell dose.  
However,  all of these characteristics are still undeter-
mined.  Currently,  a phase III,  randomized clinical trial 
focusing on intravenous transplantation and a phase II,  
randomized clinical trial focusing on intra-arterial 
transplantation are ongoing.  Additional basic and clin-
ical studies are needed for future clinical application.
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